Inicio>>Signaling Pathways>> PROTAC>> Ligand for E3 Ligase>>Lenalidomide-Br

Lenalidomide-Br

Catalog No.GC38579

Lenalidomida-Br (Compuesto 41) es un anÁlogo del ligando de cereblon (CRBN) Lenalidomida para la ubiquitina ligasa E3, y se utiliza en el reclutamiento de la proteÍna CRBN. La lenalidomida-Br se puede conectar al ligando de la proteÍna mediante un conector para formar PROTAC, como el degradador SD-36 de PROTAC STAT3.

Products are for research use only. Not for human use. We do not sell to patients.

Lenalidomide-Br Chemical Structure

Cas No.: 2093387-36-9

Tamaño Precio Disponibilidad Cantidad
100mg
36,00 $
Disponible
250mg
63,00 $
Disponible
500mg
95,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lenalidomide-Br (Compound 41) is the Lenalidomide-based ligand. Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins[1].

[1]. Bai L, et al. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019 Nov 11;36(5):498-511.e17. [2]. Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481.

Reseñas

Review for Lenalidomide-Br

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lenalidomide-Br

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.